Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00078897 · ClinicalTrials.gov registry record · Phase 3
Selenium for Prevention of Adenomatous Colorectal Polyps
A Phase 3 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,621
- Enrollment target
NCT00078897: Clinical Trial Phase 3 study, sponsored by University of Arizona.
NCT00078897 is a Phase 3 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 1,621 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (110% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00078897, a Phase 3 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,621 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Selenium may be effective in preventing the recurrence of adenomatous colorectal polyps. PURPOSE: This randomized phase III trial is studying selenium to see how well it works in preventing the recurrence of polyps in patients with adenomatous colorectal polyps.
Primary Outcome
Detection of metachronous colorectal adenomas during follow-up, by treatment, in the original cohort. Surveillance colonoscopy is recommended 3 to 5 years after removal of colorectal adenoma(s). Participants will remain on the study intervention until their surveillance colonoscopy. Surveillance colonoscopy is determined by participants' GI physician.
Interventions
- DRUG Selenium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,621 participants |
| Start Date | 2005-01-20 |
| Est. Completion | 2018-05-17 |
| Phase | Phase 3 |
Why NCT00078897 stopped before completion
NCT00078897 is an interventional study that assigns participants to a tested intervention. Its 1,621 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (110% higher).
The record links to 0 conditions, and to 1 intervention - of which Selenium is the first listed.
NCT00078897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00078897 about?
NCT00078897 is a clinical study titled "Selenium for Prevention of Adenomatous Colorectal Polyps". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Selenium may be effective in preventing the recurrence of adenomatous colorectal polyps. PURPOSE: This randomized phase III trial is studying selenium to see how well it works i...
What is the current status of trial NCT00078897?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,621 participants. The study started on 2005-01-20. Estimated completion is 2018-05-17.
What interventions are being tested in trial NCT00078897?
The interventions under investigation include: Selenium (DRUG).
Who is sponsoring clinical trial NCT00078897?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00078897's enrollment target sits among peer trials
1,621 141st of 2000 higher than 1,860 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06959524 · 1,616 participants · NA
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
- NCT06271590 · 1,605 participants · NA
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI